Literature DB >> 24660108

Significance of peripheral neutrophil-lymphocyte ratio among gastric cancer patients and construction of a treatment-predictive model: a study based on 1131 cases.

A-Man Xu1, Lei Huang1, Liang Zhu1, Zhi-Jian Wei1.   

Abstract

Gastric cancer (GC) is one of the most common and deadly malignancies nowadays, and inflammatory cells are closely related to tumor progression. This prospective study aims to uncover clinical significance of peripheral immune cells and build a treatment-predictive model. From July 2006 to July 2011, a total of 1131 GC patients were selected, with their general characteristics, peripheral blood and pathological parameters, and operational information obtained. The relevancies between preoperational neutrophil-lymphocyte ratio (NLR) and postsurgical pathological indexes were analyzed. SPSS 17.0 was applied in data analysis, comparing the differences of NLR between different groups using Mann-Whitney U test, contrasting the pathological differences between NLR elevated and reduced groups using Fisher test, and quantifying the correlation between post-surgical pathology and pre-operational NLR using univariate analysis. Patients were then classified into radical (applied in the training dataset) and non-radical gastrectomy (applied in the test dataset) groups, based on which we further tried to build a predictive model indicating appropriateness for radical resection using support vector machine (SVM). We found that: patients with tumor invading out of the myometrium (pT3-4) had significantly larger NLR than those with lesion limited within the myometrium (pT1-2) (P<0.05); poorly differentiated and undifferentiated malignancies were associated with higher NLR than well and moderately differentiated ones (P<0.05); there was larger NLR among patients with tumor length ≥4 cm than those <4 cm (P<0.01); preoperative NLR was significantly positively correlated with tumor TNM classification, number of metastatic lymph nodes, invasive depth and tumor size (P<0.05); larger proportion of elevated NLR was significantly associated with larger tumor size, later tumor and nodal stages, and higher TNM classification (P<0.01). We finally built a SVM model based on peripheral carcinoembryonic antigen, carbohydrate antigen 19-9, lymphocyte percentage and platelet count, effectively predicting the inappropriateness of patients undergoing curative gastrectomy when all the 4 parameters elevated with high accuracy (74.61% for the training dataset and 75.28% for the test dataset). We concluded that peripheral blood NLR indicated tumor progression, and that an efficient treatment-predictive SVM model was constructed.

Entities:  

Keywords:  Gastric carcinoma; gastrectomy; neutrophil-lymphocyte ratio; support vector machine; tumor progression

Year:  2014        PMID: 24660108      PMCID: PMC3960456     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  24 in total

1.  Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system.

Authors:  A el-Hag; R A Clark
Journal:  J Immunol       Date:  1987-10-01       Impact factor: 5.422

Review 2.  Paradoxical roles of the immune system during cancer development.

Authors:  Karin E de Visser; Alexandra Eichten; Lisa M Coussens
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

3.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

4.  Japanese classification of gastric carcinoma: 3rd English edition.

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

5.  Impact of immune parameters on long-term survival in metastatic renal cell carcinoma.

Authors:  Frede Donskov; Hans von der Maase
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

Review 6.  Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Authors:  Weiping Zou
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

7.  Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma.

Authors:  Dong-Ming Kuang; Qiyi Zhao; Yan Wu; Chen Peng; Jianen Wang; Zhenqun Xu; Xiao-Yu Yin; Limin Zheng
Journal:  J Hepatol       Date:  2010-11-13       Impact factor: 25.083

Review 8.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 9.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

10.  Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth.

Authors:  A McGarry Houghton; Danuta M Rzymkiewicz; Hongbin Ji; Alyssa D Gregory; Eduardo E Egea; Heather E Metz; Donna B Stolz; Stephanie R Land; Luiz A Marconcini; Corrine R Kliment; Kimberly M Jenkins; Keith A Beaulieu; Majd Mouded; Stuart J Frank; Kwok K Wong; Steven D Shapiro
Journal:  Nat Med       Date:  2010-01-17       Impact factor: 53.440

View more
  24 in total

Review 1.  Detection of digestive malignancies and post-gastrectomy complications via gastrointestinal fluid examination.

Authors:  Lei Huang; Aman Xu
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

2.  Significance of the preoperative neutrophil-to-lymphocyte ratio in the prognosis of patients with gastric cancer.

Authors:  Liang Yu; Cheng-Yu Lv; Ai-Hua Yuan; Wei Chen; An-Wei Wu
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

3.  Adenocarcinoma of esophagogastric junction: controversial classification, surgical management, and clinicopathology.

Authors:  Lei Huang; A-Man Xu
Journal:  Chin J Cancer Res       Date:  2014-06       Impact factor: 5.087

4.  Prognostic impact of platelet/lymphocyte and neutrophil/lymphocyte ratios in patients with gastric cancer: a multicenter study.

Authors:  Meral Gunaldi; Sema Goksu; Dilek Erdem; Seyda Gunduz; Yildiz Okuturlar; Eda Tiken; Sibel Kahraman; Yesim Ozdem Inan; Tugrul Burak Genc; Mustafa Yildirim
Journal:  Int J Clin Exp Med       Date:  2015-04-15

5.  Surgery combined with chemotherapy for recurrent gastric cancer achieves better long-term prognosis.

Authors:  F Kong; Y Qi; H Liu; F Gao; P Yang; Y Li; Y Jia
Journal:  Clin Transl Oncol       Date:  2015-06-19       Impact factor: 3.405

6.  Association between neutrophil-lymphocyte ratio and lymph node metastasis in gastric cancer: A meta-analysis.

Authors:  Krishna Kotecha; Animesh Singla; Philip Townend; Neil Merrett
Journal:  Medicine (Baltimore)       Date:  2022-06-24       Impact factor: 1.817

Review 7.  Epithelial-mesenchymal transition in gastric cancer.

Authors:  Lei Huang; Ruo-Lin Wu; A-Man Xu
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

8.  Transglutaminase 2 in cancer.

Authors:  Lei Huang; A-Man Xu; Wei Liu
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

9.  Prognostic impact of perioperative lymphocyte-monocyte ratio in patients with bladder cancer undergoing radical cystectomy.

Authors:  Takashi Yoshida; Hidefumi Kinoshita; Kenji Yoshida; Takao Mishima; Masaaki Yanishi; Hidekazu Inui; Yoshihiro Komai; Motohiko Sugi; Takaaki Inoue; Takashi Murota; Katsuya Fukui; Jiro Harada; Gen Kawa; Tadashi Matsuda
Journal:  Tumour Biol       Date:  2016-01-27

10.  Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer.

Authors:  C-H Koh; N Bhoo-Pathy; K-L Ng; R S Jabir; G-H Tan; M-H See; S Jamaris; N A Taib
Journal:  Br J Cancer       Date:  2015-05-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.